Aroa Biosurgery
Aroa Biosurgery Incorporated is wholly owned by Aroa Biosurgery Limited, a New Zealand-based healthcare company specializing in the development, manufacture, and distribution of advanced bioscaffold devices for soft tissue repair and wound management. Utilizing extracellular matrix (ECM) biomaterials, the company offers solutions for chronic wounds, surgical reconstruction, and dead-space management. Products are distributed internationally and supported by clinical evidence, regulatory approvals in 50+ countries, and a strong commercial presence in the US and Europe. The company maintains ISO 13485:2016 and MDSAP certifications and is publicly listed on the Australian Securities Exchange.
Industries
Nr. of Employees
large (251-1000)
Aroa Biosurgery
9155 Brown Deer Rd, Unit 2, San Diego, CA 92121, USA
Patents
Products
Finely processed bioscaffold for management of partial and full thickness wounds, ulcers, tunneled and undermined wounds, surgical and trauma wounds.
Morselized bioscaffold for management of complex wounds including partial and full thickness wounds, pressure ulcers, diabetic ulcers, surgical and traumatic wounds, and draining wounds.
Fenestrated bioscaffold tailored for application in soft tissue replacement and management of partial- and full-thickness wounds, ulcers, and surgical/traumatic wounds.
Structured bioscaffold for implantation to reinforce soft tissue in reconstructive procedures and management of wounds such as ulcers and traumatic injuries.
Combination bioscaffold containing ECM and hyaluronic acid for management of acute and chronic wounds, including ulcers, surgical, traumatic, and draining wounds.
Restorative bioscaffold indicated for acute and chronic wounds, including partial and full thickness wounds, pressure and vascular ulcers, surgical wounds, trauma wounds, and draining wounds. Compatible with negative pressure wound therapy (NPWT) in high flow format.
Finely processed bioscaffold for management of partial and full thickness wounds, ulcers, tunneled and undermined wounds, surgical and trauma wounds.
Morselized bioscaffold for management of complex wounds including partial and full thickness wounds, pressure ulcers, diabetic ulcers, surgical and traumatic wounds, and draining wounds.
Fenestrated bioscaffold tailored for application in soft tissue replacement and management of partial- and full-thickness wounds, ulcers, and surgical/traumatic wounds.
Structured bioscaffold for implantation to reinforce soft tissue in reconstructive procedures and management of wounds such as ulcers and traumatic injuries.
Combination bioscaffold containing ECM and hyaluronic acid for management of acute and chronic wounds, including ulcers, surgical, traumatic, and draining wounds.
Restorative bioscaffold indicated for acute and chronic wounds, including partial and full thickness wounds, pressure and vascular ulcers, surgical wounds, trauma wounds, and draining wounds. Compatible with negative pressure wound therapy (NPWT) in high flow format.
Expertise Areas
- Soft tissue repair and regeneration
- Wound management
- Trauma wound reconstruction
- Biomaterial product development
Key Technologies
- Extracellular matrix (ECM) bioscaffolds
- Resorbable medical biomaterials
- Vacuum-assisted tissue apposition
- Freeze-drying technologies
Key People
Founder and Chief Executive Officer
Chief Financial Officer and Joint Company Secretary
Chief Scientific Officer
Chief of Technical Operations
Founder and Chief Executive Officer
Chief Financial Officer and Joint Company Secretary
Chief Scientific Officer
Chief of Technical Operations
News & Updates
Received awards for innovation and business excellence at regional business awards.
Founder and CEO Dr Brian Ward recognized for contributions to the biotech sector.
Interim analysis from the MASTRR Registry demonstrates low infection rates and no device-related adverse events in over 400 patients with soft tissue defects.
First-in-human clinical evaluation of a tissue apposition device for dead space management shows promising results in post-mastectomy healing.
Retrospective case series in ePlasty describes positive outcomes for bioscaffold use in trauma reconstruction, including rapid soft tissue coverage and no complications.
Peer-reviewed study demonstrates compatibility of high-flow bioscaffold with negative pressure wound therapy systems.
Received awards for innovation and business excellence at regional business awards.
Founder and CEO Dr Brian Ward recognized for contributions to the biotech sector.
Interim analysis from the MASTRR Registry demonstrates low infection rates and no device-related adverse events in over 400 patients with soft tissue defects.
First-in-human clinical evaluation of a tissue apposition device for dead space management shows promising results in post-mastectomy healing.
Retrospective case series in ePlasty describes positive outcomes for bioscaffold use in trauma reconstruction, including rapid soft tissue coverage and no complications.
Peer-reviewed study demonstrates compatibility of high-flow bioscaffold with negative pressure wound therapy systems.